Nicox (NICXF) Change In Receivables : $1.70 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Nicox Change In Receivables?

Nicox's change in receivables for the quarter that ended in Jun. 2023 was $1.46 Mil. It means Nicox's Accounts Receivable declined by $1.46 Mil from Dec. 2022 to Jun. 2023 .

Nicox's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.03 Mil. It means Nicox's Accounts Receivable increased by $0.03 Mil from Dec. 2021 to Dec. 2022 .

Nicox's Accounts Receivable for the quarter that ended in Jun. 2023 was $2.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nicox's Days Sales Outstanding for the six months ended in Jun. 2023 was 125.80.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nicox's liquidation value for the six months ended in Jun. 2023 was $-17.67 Mil.

Nicox Change In Receivables Historical Data

The historical data trend for Nicox's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Change In Receivables Chart

Nicox Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-1.29

0.42

-2.03

-0.50

-0.03

Nicox Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															0.47	-0.94	-0.26	0.24	1.46

Nicox Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.70 Mil.

Nicox (OTCPK:NICXF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nicox's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.07	/	3.003	*	91
=	125.80

2. In Ben Graham's calculation of liquidation value, Nicox's accounts receivable are only considered to be worth 75% of book value:

Nicox's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	20.597	-	39.819	+	0.75 * 2.07	+	0.5 * 0
=	-17.67

Nicox Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nicox's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALCOX:France NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021